Results 91 to 100 of about 675,780 (316)

Staining of BxPC-3 cells with anti-CEA antibody and quantification of binding sites.

, 2015
BxPC-3 cells were treated with anti-CEA antibody and stained with a fluorochrome conjugated secondary antibody against anti-CEA (red, filled), or control-stained with secondary antibody only (black, open) and analyzed by flow cytometry.
Yukihiko Hiroshima (568068), Roger Heim (709675), Ali A. Maawy (568067), George A. Luiken (568069), Miguel Garcia-Guzman (709677), Robert M. Hoffman (302618), Lew Makings (709676), Hisataka Kobayashi (1859), Yong Zhang (5893), Michael Bouvet (483662)   +9 more
core   +1 more source

Screening and identification of human HPV18VLP neutralizing antibodies from women receiving HPV vaccine

Frontiers in Immunology
Currently, the primary treatments for cervical cancer patients are surgery or chemoradiotherapy, with a lack of standardized pharmacological therapies. Here, we report the construction of a Fab fragment phage display antibody library with a capacity of ...
Yaru Gu, Yaru Gu, Rui Zhang, Wenhao Wang, Jinrui Zhou, Bixia Liu, Yan Zheng, Houyi Zuo, Yexiang Du, Ying Wang, Renjian Hu, Qianfei Zuo   +11 more
doaj   +1 more source

Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition

Molecules, 2020
Vaccines and immunotherapies depend on the ability of antibodies to sensitively and specifically recognize particular antigens and specific epitopes on those antigens.
Benjamin D. Brooks, Adam Closmore, Juechen Yang, Michael Holland, Tina Cairns, Gary H. Cohen, Chris Bailey-Kellogg   +6 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

mAbs, 2019
The neonatal Fc receptor (FcRn) promotes antibody recycling through rescue from normal lysosomal degradation. The binding interaction is pH-dependent with high affinity at low pH, but not under physiological pH conditions.
Brian C. Mackness, Julie A. Jaworski, Ekaterina Boudanova, Anna Park, Delphine Valente, Christine Mauriac, Olivier Pasquier, Thorsten Schmidt, Mostafa Kabiri, Abdullah Kandira, Katarina Radošević, Huawei Qiu   +11 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites

Molecular Therapy: Methods & Clinical Development
Lipid nanoparticles (LNPs) are often liver tropic, presenting challenges for LNP-delivered mRNA therapeutics intended for other tissues, as off-target expression in the liver may increase side effects and modulate immune responses.
Brian J. Parrett, Satoko Yamaoka, Michael A. Barry   +2 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Antibody Conjugates via Disulfide Bridging: Towards therapeutic and diagnostic applications

, 2015
Antibodies play a prominent role in chemical and biological research and the largest application of chemical bioconjugation reagents is in the production of antibody conjugates.
Hull, EA
core